Progressive endothelial damage revealed by multilevel von Willebrand factor plasma concentrations in atrial fibrillation patients

Europace

Volumn 15, Issue 11, 2013, Pages 1562-1566

  Scridon, Alina ^a,b   Girerd, Nicolas ^c   Rugeri, Lucia ^d   Nonin Babary, Emilie ^c   Chevalier, Philippe ^a,c  

^a UNIVERSITÉ LYON 1   (France)

^b UNIVERSITY OF MEDICINE AND PHARMACY   (Romania)

^c LOUIS PRADEL HOSPITAL   (France)

^d EDOUARD HERRIOT HOSPITAL   (France)

Author keywords

Atrial fibrillation; Endothelial dysfunction; Stroke; von Willebrand factor

Indexed keywords

C REACTIVE PROTEIN; VON WILLEBRAND FACTOR; BIOLOGICAL MARKER;

ADULT; ARTICLE; ATRIAL FIBRILLATION; BLOOD SAMPLING; CEREBROVASCULAR ACCIDENT; CHA2DS2-VASC SCORE; CONTROLLED STUDY; CORONARY SINUS; CROSS-SECTIONAL STUDY; ENDOTHELIAL DYSFUNCTION; FEMALE; FEMORAL VEIN; HEART CATHETERIZATION; HEART LEFT ATRIUM; HIGH RISK PATIENT; HUMAN; IMMUNOTURBIDIMETRY; INTERMEDIATE RISK PATIENT; LOW RISK PATIENT; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; PAROXYSMAL ATRIAL FIBRILLATION; PERSISTENT ATRIAL FIBRILLATION; PRIORITY JOURNAL; SINUS RHYTHM; WOLFF PARKINSON WHITE SYNDROME; BLOOD; CASE CONTROL STUDY; DISEASE COURSE; HEART ATRIUM FIBRILLATION; METABOLISM; PATHOPHYSIOLOGY; RISK FACTOR; SINUS NODE; THROMBOEMBOLISM; VASCULAR ENDOTHELIUM;

ATRIAL FIBRILLATION; ENDOTHELIAL DYSFUNCTION; STROKE; VON WILLEBRAND FACTOR;

ATRIAL FIBRILLATION; BIOLOGICAL MARKERS; CASE-CONTROL STUDIES; CROSS-SECTIONAL STUDIES; DISEASE PROGRESSION; ENDOTHELIUM, VASCULAR; FEMALE; HUMANS; MALE; MIDDLE AGED; RISK FACTORS; SINOATRIAL NODE; STROKE; THROMBOEMBOLISM; VON WILLEBRAND FACTOR; WOLFF-PARKINSON-WHITE SYNDROME;

EID: 84897427207     PISSN: 10995129     EISSN: 15322092     Source Type: Journal    
DOI: 10.1093/europace/eut121     Document Type: Article

References (23)

1. Savelieva I, Bajpai A, Camm AJ. Stroke in atrial fibrillation: Update on pathophysiology, new antithrombotic therapies, and evolution of procedures and devices. Ann Med 2007;39:371-91.
2. Lip GY. Anticoagulation therapy and the risk of stroke in patients with atrial fibrillation at 'moderate risk' [CHADS2 scor1]: Simplifying stroke risk assessment and thromboprophylaxis in real-life clinical practice. Thromb Haemost 2010;103:683-5.
3. Lip GY. Stroke in atrial fibrillation: Epidemiology and thromboprophylaxis. J Thromb Haemost 2011;9:344-51.
4. Lip GY. Does atrial fibrillation confer a hypercoagulable state? Lancet 1995;346: 1313-4.
5. Pollick C, Taylor D. Assessment of left atrial appendage function by transesophageal echocardiography. Implications for the development of thrombus. Circulation 1991; 84:223-31.
6. Thambidorai SK, Murray RD, Parakh K, Shah TK, Black IW, Jasper SE et al. Utility of transesophageal echocardiography in identification of thrombogenic milieu in patients with atrial fibrillation (an ACUTE ancillary study). Am J Cardiol 2005;96: 935-41.
7. de Divitiis M, Omran H, Rabahieh R, Rang B, Illien S, Schimpf R et al. Right atrial appendage thrombosis in atrial fibrillation: Its frequency and its clinical predictors. Am J Cardiol 1999;84:1023-8.
8. Kaireviciute D, LipGY, Balakrishnan B, UzdavinysG, Norkunas G, KalinauskasGet al. Intracardiac expression of markers of endothelial damage/dysfunction, inflammation, thrombosis, and tissue remodeling, and the development of postoperative atrial fibrillation. J Thromb Haemost 2011;9:2345-52.
9. Choudhury A, Lip GY. Atrial fibrillation and the hypercoagulable state. Pathophysiol Haemost Thromb 2003;33:282-9.
10. Gustafsson C, Blombäck M, Britton M, Hamsten A, Svensson J. Coagulation factors and the increased risk of stroke in nonvalvular atrial fibrillation. Stroke 1990;21: 47-51.
11. Heppell RM, Berkin KE, McLenachan JM, Davies JA. Haemostatic and haemodynamic abnormalities associated with left atrial thrombosis in non-rheumatic atrial fibrillation. Heart 1997;77:407-11.
12. Mondillo S, Sabatini L, Agricola E, Ammaturo T, Guerrini F, Barbati R et al. Correlation between left atrial size, prothrombotic state and markers of endothelial dysfunction in patients with lone chronic nonrheumatic atrial fibrillation. Int J Cardiol 2000;75:227-32.
13. Wieberdink RG, van Schie MC, Koudstaal PJ, Hofman A, Witteman JC, de Maat MP et al. High von Willebrand factor levels increase the risk of stroke. The Rotterdam study. Stroke 2010;41:2151-6.
14. Camm AJ, Kirchhof P, Lip GY, Schotten U, Savelieva I, Ernst S et al. Guidelines for the management of atrial fibrillation: The task force for the management of atrial fibrillation of the European Society of Cardiology (ESC). Europace 2010;12:1360-420.
15. Sakariassen KS, Bolhuis PA, Sixma JJ. Human blood platelet adhesion to artery subendothelium is mediated by factor VIII-Von Willebrand factor bound to the subendothelium. Nature 1979;279:636-8.
16. Jones TR, Kao KJ, Pizzo SV, Bigner DD. Endothelial cell surface expression and binding of factor VIII/von Willebrand factor. Am J Pathol 1981;103:304-8.
17. Fukuchi M,Watanabe J, Kumagai K, Katori Y, Baba S, Fukuda K et al. Increased von Willebrand factor in the endocardium as a local predisposing factor for thrombogenesis in overloaded human atrial appendage. J Am Coll Cardiol 2001;37:1436-42.
18. Freestone B, Lip GY. The endothelium and atrial fibrillation. The prothrombotic state revisited. Hamostaseologie 2008;28:207-12.
19. Cai H, Li Z, Goette A, Mera F, Honeycutt C, Feterik K et al. Downregulation of endocardial nitric oxide sinthase expression and nitric oxide production in atrial fibrillation. Potential mechanisms for atrial thrombosis and stroke. Circulation 2002;106:2854-8.
20. Yamashita T, Sekiguchi A, Iwasaki YK, Sagara K, Hatano S, Iinuma H et al. Thrombomodulin and tissue factor pathway inhibitor in endocardium of rapidly paced rat atria. Circulation 2003;108:2450-2.
21. Iwasaki YK, Nishida K, Kato T, Nattel S. Atrial fibrillation pathophysiology: Implications for management. Circulation 2011;124:2264-74.
22. Sadler JE. Biochemistry and genetics of von Willebrand factor. Annu Rev Biochem 1998;67:395-424.
23. Conway DSG, Pearce LA, Chin BSP, Hart RG, Lip GYH. Prognostic value of plasma von Willebrand factor and soluble P-selectin as indices of endothelial damage and platelet activation in 994 patients with nonvalvular atrial fibrillation. Circulation 2003;107:3141-5.